Open AccessHelicobacter Pylori as a Risk Factor for Post Infectious Irritable Bowel Syndrome
Author(s) -
Essamaddin Ahmed Abdelhamid Ibrahim,
AUTHOR_ID
Publication year - 2022
Publication title -
journal of infectious diseases and case reports
Language(s) - English
Resource type - Journals
ISSN - 2634-8861
DOI - 10.47363/jidscr/2022(3)155
Subject(s) - irritable bowel syndrome , medicine , helicobacter pylori , gastroenterology , amoxicillin , clarithromycin , metronidazole , proton pump inhibitor , antibiotics , microbiology and biotechnology , biology
Backgrounds: Helicobacter Pylori is a common pathogen leading cause of peptic ulcer disease. Several studies linked Helicobacter Pylori infection and the development of irritable bowel syndrome. Aims: We investigated the effectiveness of standard triple therapy and the association between H.Pylori infection and the development of post infectious irritable bowel syndrome. Materials and methods: Prospective analytical study was conducted and we appointed 200 H.Pylori positive patients, they consented and subjected to structured questionnaire and received standard triple therapy (14 days course of proton pump inhibitor (PPI), clarithromycin and either amoxicillin or metronidazole). After three months all patients re-evaluated regarding their symptoms and tested for eradication. Additionally we evaluated the association between H.Pylori infection and irritable bowel syndrome